Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Share-based Compensation (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Share-based Compensation for 13 consecutive years, with $20.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 28.6% year-over-year to $20.1 million, compared with a TTM value of $92.4 million through Dec 2025, down 8.88%, and an annual FY2025 reading of $92.4 million, down 8.88% over the prior year.
  • Share-based Compensation was $20.1 million for Q4 2025 at Tandem Diabetes Care, down from $21.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $28.2 million in Q4 2024 and bottomed at $12.9 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $21.4 million, with a median of $21.6 million recorded in 2023.
  • The sharpest move saw Share-based Compensation soared 42.94% in 2022, then dropped 28.6% in 2025.
  • Year by year, Share-based Compensation stood at $17.1 million in 2021, then soared by 42.94% to $24.4 million in 2022, then dropped by 6.96% to $22.7 million in 2023, then grew by 23.86% to $28.2 million in 2024, then dropped by 28.6% to $20.1 million in 2025.
  • Business Quant data shows Share-based Compensation for TNDM at $20.1 million in Q4 2025, $21.1 million in Q3 2025, and $25.6 million in Q2 2025.